Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parkedale Turns To Consultants After FDA Halts Fluogen Production

Executive Summary

Parkedale Pharmaceuticals is drawing on advice from regulatory consultants The Biologics Consulting Group and regulatory legal counsel Arnold and Porter in "evaluating strategies pertaining to Fluogen," the company said.

You may also be interested in...



King Fluogen Discontinued; Flu Vaccine Would Have Been Unavailable In 2000

King Pharmaceuticals will discontinue Fluogen following receipt of a Sept. 27 FDA letter concerning the flu vaccine.

King Fluogen Discontinued; Flu Vaccine Would Have Been Unavailable In 2000

King Pharmaceuticals will discontinue Fluogen following receipt of a Sept. 27 FDA letter concerning the flu vaccine.

Powderject Moves Into Marketing Phase Via Medeva Vaccines Acquisition

Powderject's acquisition of Medeva's vaccines business moves the company from the research phase into the marketing of six products, one of which is sold in the U.S.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel